Thromb Haemost 1987; 58(01): 472
DOI: 10.1055/s-0038-1644545
Abstracts
PLATELET AGGREGATION
Schattauer GmbH Stuttgart

RIBAVIRIN: STUDIES OF THE EFFECTS OF THE ANTIVIRAL DRUG ON PLATELET FUNCTION

T M Cosgriff
1   United States Army Medical Research Institute of Infectious Diseases, Ft. Detrick, Frederick, MD 21701-5011, U.S.A
,
P G Canonico
1   United States Army Medical Research Institute of Infectious Diseases, Ft. Detrick, Frederick, MD 21701-5011, U.S.A
,
L Hodgson
1   United States Army Medical Research Institute of Infectious Diseases, Ft. Detrick, Frederick, MD 21701-5011, U.S.A
,
D Parrish
1   United States Army Medical Research Institute of Infectious Diseases, Ft. Detrick, Frederick, MD 21701-5011, U.S.A
,
T Chapman
1   United States Army Medical Research Institute of Infectious Diseases, Ft. Detrick, Frederick, MD 21701-5011, U.S.A
,
J W Huggins
1   United States Army Medical Research Institute of Infectious Diseases, Ft. Detrick, Frederick, MD 21701-5011, U.S.A
,
Z-J Gong
2   Hubei Medical College, Wuhan, Hubei, Peoples Republic of China
,
L-B Xiang
2   Hubei Medical College, Wuhan, Hubei, Peoples Republic of China
,
C-H Hsiang
2   Hubei Medical College, Wuhan, Hubei, Peoples Republic of China
› Author Affiliations
Further Information

Publication History

Publication Date:
23 August 2018 (online)

Preview

Ribavirin is a broad-spectrum antiviral drug which is presently undergoing testing in patients with AIDS-related complex. It has also been shown to have activity against respiratory syncytial virus, Sicilian sandfly fever virus, influenza A and B viruses, as well as several hemorrhagic fever viruses. It has proved effective in clinical trials in Lassa fever and shows promise as therapy for hemorrhagic fever with renal syndrome. Because platelet dysfunction may contribute significantly to hemostatic impairment in viral hemorrhagic fever, the effects of ribavirin on platelet function were measured in rhesus monkeys after daily injections of 100 mg/kg IM for 14 days. Drug administration led to a significant increase in platelet count associated with megakaryocyte hyperplasia but had no effect on aggregation of platelet-rich plasma (PRP) in response to either collagen (1.6 μg/ml) or ADP (10 μM/ml). Aggregation in whole blood was also unaffected. Addition of ribavirin to human PRP in concentrations up to 0.5 mg/ml had no effect on aggregation in response to collagen, ADP, or epinephrine (5 μg/ml). Preliminary data from Chinese patients treated with ribavirin for hemorrhagic fever with renal syndrome also reveal no evidence of drug-induced platelet dysfunction as indicated by normal aggregation and release reactions to collagen (3 μg/ml) and ADP (10 μM/ml). Bone marrow studies of megakaryocyte number and ploidy are presently underway to further characterize drug-associated thrombocytosis